scholarly journals Safety and Long-Term Efficacy of Eculizumab in a Renal Transplant Patient with Recurrent Atypical Hemolytic-Uremic Syndrome

2009 ◽  
Vol 9 (11) ◽  
pp. 2644-2645 ◽  
Keyword(s):  
Renal Transplant ◽  
Hemolytic Uremic Syndrome ◽  
Renal Transplant Patient ◽  
Transplant Patient ◽  
Atypical Hemolytic Uremic Syndrome ◽  
Term Efficacy ◽  
Uremic Syndrome

Long-Term Carriage of Medicopsis romeroi, an Agent of Black-Grain Mycetoma, Presenting as Phaeohyphomycosis in a Renal Transplant Patient

2019 ◽  
Vol 184 (5) ◽  
pp. 671-676 ◽  
Author(s):  
Joshua A. Lieberman ◽  
Joseph Fiorito ◽  
Doug Ichikawa ◽  
Ferric C. Fang ◽  
Robert M. Rakita ◽  
...  
Keyword(s):  
Renal Transplant ◽  
Renal Transplant Patient ◽  
Transplant Patient

scholarly journals Pre-emptive Eculizumab and Plasmapheresis for Renal Transplant in Atypical Hemolytic Uremic Syndrome

2011 ◽  
Vol 6 (6) ◽  
pp. 1488-1494 ◽  
Author(s):  
Carla Nester ◽  
Zoe Stewart ◽  
David Myers ◽  
Jennifer Jetton ◽  
Ramesh Nair ◽  
...  
Keyword(s):  
Renal Transplant ◽  
Hemolytic Uremic Syndrome ◽  
Atypical Hemolytic Uremic Syndrome ◽  
Uremic Syndrome

scholarly journals Long-term renal function under plasma exchange in atypical hemolytic uremic syndrome

2011 ◽  
Vol 26 (10) ◽  
pp. 1915-1916 ◽  
Author(s):  
Jean-Claude Davin ◽  
Jaap Groothoff ◽  
Valentina Gracchi ◽  
Antonia Bouts
Keyword(s):  
Renal Function ◽  
Hemolytic Uremic Syndrome ◽  
Plasma Exchange ◽  
Atypical Hemolytic Uremic Syndrome ◽  
Uremic Syndrome

Long-term successful liver–kidney transplantation in a child with atypical hemolytic uremic syndrome caused by homozygous factor H deficiency

2016 ◽  
Vol 31 (12) ◽  
pp. 2375-2378 ◽  
Author(s):  
Emmanuel Gonzales ◽  
Tim Ulinski ◽  
Dalila Habes ◽  
Georges Deschênes ◽  
Véronique Frémeaux-Bacchi ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Hemolytic Uremic Syndrome ◽  
Atypical Hemolytic Uremic Syndrome ◽  
Factor H ◽  
Factor H Deficiency ◽  
Uremic Syndrome

scholarly journals Clinical-Laboratory- Genetic Profile and Outcomes of Patients with Atypical Hemolytic Uremic Syndrome and Restrictive Use of Eculizumab: A Single Center Experience and a Brief Review

Blood ◽  
2021 ◽  
Vol 138 (Supplement 1) ◽  
pp. 3159-3159
Author(s):  
Fnu Amisha ◽  
Manojna Konda ◽  
Paras Malik ◽  
Arya Mariam Roy ◽  
Appalanaidu Sasapu
Keyword(s):  
Hemolytic Uremic Syndrome ◽  
Atypical Hemolytic Uremic Syndrome ◽  
Factor H ◽  
Genetic Profile ◽  
Complement Factor ◽  
Single Center ◽  
Inclusion Criteria ◽  
Atypical Hus ◽  
Uremic Syndrome

Abstract Background Atypical HUS (aHUS) is a rare thrombotic microangiopathy (TMA) caused by complement dysregulation. Eculizumab is a humanized monoclonal antibody targeting against complement factor C5. Ravulizumab, a longer acting C5 inhibitor developed through minimal, targeted modifications to eculizumab was recently approved for treatment of aHUS in 2019. Here we describe the clinical presentation, laboratory, genetic profile, treatment along with long-term sequelae of patients diagnosed with aHUS. The outcomes of restrictive use of eculizumab and the use of ravulizumab were also studied. Materials and Methods We conducted a single center retrospective cohort study, searching electronic medical records of patients diagnosed and treated for aHUS at University of Arkansas for Medical Sciences, from January 1, 2013 to January 31, 2021, after IRB approval. Inclusion criteria :1) Presence of microangiopathic hemolytic anemia (MAHA) with thrombocytopenia 2) ADAMTS13 activity > 10 % 3) Age > 18. Exclusion criteria: 1) Age < 18 years 2) TMA associated with hemolytic uremic syndrome, scleroderma renal crises, anti-phospholipid syndrome. Results Seventeen patients meeting the inclusion criteria were enrolled in the study. The mean age at diagnosis was 47.4 ± 17.9 years. Most of the patients were Caucasians (n=10, 58%) and females (n= 14, 82%). All the patients except one had acute kidney injury (AKI) at presentation (n=16, 94.1%), the most frequent extra-renal presentation was CNS involvement -seizures, confusion and altered mental status (n= 7, 41.2 %) followed by Gastrointestinal- non-bloody diarrhea, nausea and vomiting (n=5, 29.4 %) [Figure 1]. Lab investigations are described in [Table 1]. Complement genetic testing was done in 100% of study population. Factor H related genes 1/3 (CFHR1/3) and complement factor H (CFH) were the most commonly found pathogenic mutations [Table 2]. In this study, pregnancy and infection (n= 4, 23.5% each) were identified as the most common triggers [Figure 2]. For two of the patients, it was the first pregnancy and for the other two, it was their second and third pregnancies. They presented at the second, sixth, and sixteenth week postpartum respectively. Eleven (64.70%) patients developed chronic kidney disease (CKD) with six (35.29%) patients progressing to end stage renal disease (ESRD). Two (11.76 %) pregnant patients developed cardiomyopathy, two (11.76%) patients developed pulmonary complications (pneumonia and pulmonary hypertension) and three (17.64%) patients developed epilepsy. All the postpartum females in our study were able to breastfeed while on eculizumab with no long-term complications in the neonates. One patient had two subsequent deliveries with no ante, intra, or post-partum consequences or repeated triggers of aHUS. Fourteen patients (82.3%) received therapeutic plasma exchange, four (23.5%) patients received iv methyl prednisone (1mg/kg) and two (11.7%) patients received IVIg prior to initiating eculizumab. Over time, five (29.41%) patients opted to completely stop drug therapy and four patients (23.52%) chose to shift to ravulizumab because of the ease of treatment duration (every 8 weeks rather than every 2 weeks for eculizumab). All these nine patients remained in remission with stable hematologic and renal parameters on subsequent follow-ups [Table 3]. Three patients (17.6 % mortality) died in our study due to causes unrelated to aHUS. Conclusions: The clinical diagnosis of atypical HUS can be challenging especially with extra-renal manifestations. Females were four times more affected than males. PCMs were present in 11 patients. Early diagnosis and treatment with C5 inhibitors improves morbidity and mortality. The decision to discontinue or switch eculizumab to ravulizumab will likely decrease healthcare costs and improve patient compliance but should be based on disease severity. Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare.

Case Report: Benefits and Challenges of Long-term Eculizumab in Atypical Hemolytic Uremic Syndrome

PEDIATRICS ◽  
2015 ◽  
Vol 135 (6) ◽  
pp. e1506-e1509 ◽  
Author(s):  
N. Cullinan ◽  
K. M. Gorman ◽  
M. Riordan ◽  
M. Waldron ◽  
T. H. J. Goodship ◽  
...  
Keyword(s):  
Case Report ◽  
Hemolytic Uremic Syndrome ◽  
Atypical Hemolytic Uremic Syndrome ◽  
Uremic Syndrome
Sign in / Sign up

Export Citation Format

Share Document